Nasdaq · CIK 0001641489
VTVT vTv Therapeutics Inc.
Insider trading from SEC Form 4. Last filing Jun 12, 2025. Close $31.18 on Oct 9, 2026, +54% from the 52-week low and -27% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
5
with a Form 4 at this company
Price and insider trades, last year
VTVTOct 9, 2026 · close 31.18
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at vTv Therapeutics Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 27Weak | Paul J Sekhri Pres, CEO and Exec Chairperson buy | $84k 5,000 shares | - | - |
Transactions
The last 13 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 10, 2025 | Baker Bros. Advisors LP director | AGrant or award Non- Qualified Stock Option (right to buy)derivativeindirect: See Footnotes | +4,000 | $0.00 | $0 | 4,000 | Jun 12, 2025 |
| Jun 10, 2025 | Srinivas Akkaraju director | AGrant or award Director stock option (right to buy)derivative | +4,000 | $16.59 | $66k | 10,983 | Jun 12, 2025 |
| Jun 10, 2025 | Fahed Al-Marzooqi director | AGrant or award Director stock option (right to buy)derivative | +4,000 | $16.59 | $66k | 13,555 | Jun 12, 2025 |
| Jun 10, 2025 | Baker Bros. Advisors LP director | AGrant or award Non- Qualified Stock Option (right to buy)derivativeindirect: See Footnotes | +4,000 | $0.00 | $0 | 4,000 | Jun 12, 2025 |
| Jun 25, 2024 | Srinivas Akkaraju director | AGrant or award Director stock option (right to buy)derivative | +2,250 | $17.22 | $39k | 6,000 | Apr 24, 2025 |
| Jun 25, 2024 | Srinivas Akkaraju director | AGrant or award Director stock option (right to buy)derivative | +983 | $17.22 | $17k | 6,983 | Apr 24, 2025 |
| Mar 5, 2024 | Srinivas Akkaraju director, owner | DDisposition to issuer Class A Common Stockindirect: By Samsara BioCapital, L.P. | -58,836 | - | - | 206,784 | Dec 6, 2024 |
| Mar 5, 2024 | Samsara BioCapital GP, LLC owner | JOther Class A Common Stockindirect: By Samsara BioCapital, L.P. | -58,836 | - | - | 206,784 | Dec 6, 2024 |
| Mar 5, 2024 | Srinivas Akkaraju director, owner | AGrant or award Pre- Funded Warrants (Right to Buy)derivativeindirect: Samsara BioCapital, L.P. | +58,885 | - | - | 892,578 | Dec 6, 2024 |
| Mar 5, 2024 | Samsara BioCapital GP, LLC owner | AGrant or award Pre- Funded Warrants (Right to Buy)derivativeindirect: Samsara BioCapital, L.P. | +58,885 | - | - | 892,578 | Dec 6, 2024 |
| Nov 15, 2024 | Paul J Sekhri Pres, CEO and Exec Chairperson | POpen-market purchase Class A Common Stock10b5-1 | +1,378 | $16.35 | $23k | 1,378 | Nov 19, 2024 |
| Nov 15, 2024 | Paul J Sekhri Pres, CEO and Exec Chairperson | POpen-market purchase Class A Common Stock10b5-1 | +1,778 | $16.88 | $30k | 3,156 | Nov 19, 2024 |
| Nov 18, 2024 | Paul J Sekhri Pres, CEO and Exec Chairperson | POpen-market purchase Class A Common Stock10b5-1 | +1,844 | $16.96 | $31k | 5,000 | Nov 19, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Srinivas Akkarajuowner, director
- Fahed Al-Marzooqidirector
- Baker Bros. Advisors LPdirector, owner
- Paul J SekhriPres, CEO and Exec Chairperson
- Samsara BioCapital GP, LLCowner
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.